MedTrace Logo

Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis

NCT01245998 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2018-05-04

No results posted yet for this study

Summary

The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein thrombosis and pulmonary embolism), whether efficacy of low-molecular-weight heparin differs with regard to the dosage used (prevention, treatment), and to recognize groups of patients in which treatment with heparin is most efficient, as well as to determine factors that influence the efficacy of SVT treatment with heparin.

Conditions

  • Superficial Thrombophlebitis

Interventions

DRUG

Dalteparin

dalteparin 5000 I.U./24 h s.c. for 6 weeks

DRUG

Dalteparin

dalteparin 15000 I.U./24 h s.c. for 6 weeks

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Pavel Poredos, M.D., Ph.D. · University Medical Centre Ljubljana, Department of Vascular Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-01
Primary Completion
2012-12-03
Completion
2014-01-01

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245998 on ClinicalTrials.gov